Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo shows promise for Tough-to-Treat leukemia

NCT ID NCT05199051

First seen Jan 09, 2026 · Last updated May 25, 2026 · Updated 22 times

Summary

This study tests a new two-drug combination for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to initial treatment. The drugs target a genetic change (FLT3 mutation) found in some AML patients. The goal is to see if the combination is safe and can help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHMS de Chambery

    Chambéry, France

  • CHRU Nancy

    Nancy, France

  • CHU Bordeaux

    Bordeaux, France

  • CHU Limoges

    Limoges, France

  • CHU d'Amiens

    Amiens, France

  • CHU d'Angers

    Angers, France

  • CHU de Caen

    Caen, France

  • Centre Henri Becquerel

    Rouen, France

  • Centre Hospitalier Universitaire de Nice

    Nice, France

  • Centre Hospitalier de Versailles

    Versailles, France

  • HIA Percy

    Clamart, France

  • Hôpital Saint Louis

    Paris, France

Conditions

Explore the condition pages connected to this study.